Story perspectives

RT CHARM Trial Finds 3-Week Radiation Noninferior to 5-Week

By Drooid · Oct 23, 2026, 11:07 PM UTC · How we work

Summary

Story summary

Dr. Matthew Poppe reported a three-week radiation regimen is noninferior to the standard five-week schedule for breast reconstruction patients.
The RT CHARM trial enrolled 898 women with unilateral invasive breast cancer at 209 U.S. and Canadian sites.
Complication rates at 24 months were 12.3% vs 10.2%, meeting the 10% noninferiority margin (P = .0001).
Acute grade 2 dermatitis occurred in 20% of hypofractionated patients versus 42% of conventional patients (P < .0001).

1 of 1

Story summary

Dr. Matthew Poppe reported a three-week radiation regimen is noninferior to the standard five-week schedule for breast reconstruction patients.
The RT CHARM trial enrolled 898 women with unilateral invasive breast cancer at 209 U.S. and Canadian sites.
Complication rates at 24 months were 12.3% vs 10.2%, meeting the 10% noninferiority margin (P = .0001).
Acute grade 2 dermatitis occurred in 20% of hypofractionated patients versus 42% of conventional patients (P < .0001).